title: A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.
abstract: Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNgamma expression and macrophage activation during IFNbeta-1a treatment. Predose levels of beta2-MG increased, the significance of which is as yet unclear.
authors: Department of Neurological Sciences, University La Sapienza, Rome, Italy. francesca.bagnato@uniroma1.it
authors: F
authors: F
authors: Bagnato
authors: C
authors: C
authors: Pozzilli
authors: C
authors: C
authors: Scagnolari
authors: F
authors: F
authors: Bellomi
authors: P
authors: P
authors: Pasqualetti
authors: C
authors: C
authors: Gasperini
authors: E
authors: E
authors: Millefiorini
authors: S
authors: S
authors: Galgani
authors: M
authors: M
authors: Spadaro
authors: G
authors: G
authors: Antonelli
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D016014:Linear Models; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy*; D019798:Neopterin / Q000097:blood*; D012008:Recurrence; D013995:Time; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: D001613:beta 2-Microglobulin; D019798:Neopterin; D016899:Interferon-beta; D000068556:Interferon beta-1a